Holistic View of Tirzepatide's Role in Obesity-Related HFpEF
- PMID: 40063724
- DOI: 10.1161/CIRCULATIONAHA.125.073439
Holistic View of Tirzepatide's Role in Obesity-Related HFpEF
Keywords: Editorials; heart failure with preserved ejection fraction; obesity; tirzepatide.
Conflict of interest statement
N.J.P. reports research support from Alnylam, Amgen, Bayer, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, and Merck; consultation/advisory panels for Amgen, Bayer, Boehringer Ingelheim, Corcept, Corsera, Eli Lilly, Esperion, AstraZeneca, Merck, New Amsterdam, Novartis, and Novo Nordisk; trial leadership for Novo Nordisk, Novartis, Alnylam, AstraZeneca, and Amgen; Data Safety Monitoring Board for trials sponsored by Janssen and Novartis; and medical advisory board for Miga Health.
Comment on
-
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.Circulation. 2025 Mar 11;151(10):656-668. doi: 10.1161/CIRCULATIONAHA.124.072679. Epub 2024 Nov 18. Circulation. 2025. PMID: 39556714 Free PMC article. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
